Can I Take Melatonin with Wegovy?

Why This Question Comes Up So Often

Sleep disruption is common during active weight loss. Between 25% and 50% of adults on calorie-restricted regimens report worsened sleep quality, according to a 2022 systematic review in Obesity Reviews [1]. Wegovy's prescribing information also lists fatigue and insomnia among reported adverse events during the STEP clinical program [2]. Patients naturally reach for melatonin, the most popular sleep supplement in the United States, with roughly 6.1% of U.S. Adults reporting use in the prior 30 days per the 2023 NHIS supplemental survey [3].

The Core Concern

The worry is not that melatonin will block Wegovy's weight-loss effect. It is that melatonin, especially at higher doses, influences insulin secretion and glucose handling. Semaglutide improves glycemic control partly by potentiating glucose-dependent insulin release [4]. If melatonin blunts that same pathway at night, the two agents could partially oppose each other on a metabolic level.

What the Evidence Actually Shows

No published randomized controlled trial has directly tested melatonin co-administration with semaglutide. The clinical picture must be assembled from pharmacology fundamentals, melatonin-glucose studies, and the known metabolic profile of GLP-1 receptor agonists.

Pharmacokinetic Profile: No Meaningful Drug-Supplement Interaction

Semaglutide 2.4 mg is a long-acting GLP-1 receptor agonist injected subcutaneously once weekly. Its half-life is approximately 7 days, and it is eliminated through proteolytic degradation rather than cytochrome P450 metabolism [4]. Melatonin, by contrast, is primarily metabolized by CYP1A2 in the liver, with minor contributions from CYP2C19 [5].

Different Pathways, No Competition

Because these two compounds do not share metabolic enzymes, neither one alters the plasma concentration of the other. Semaglutide does slow gastric emptying, which could theoretically delay absorption of oral supplements [4]. For melatonin taken at bedtime (hours after any meal), this effect is minimal.

Bioavailability Considerations

Oral melatonin bioavailability ranges from 3% to 33%, with considerable inter-individual variation driven by first-pass hepatic metabolism [5]. Semaglutide-induced gastroparesis would only matter if melatonin were taken with a large meal, where delayed gastric transit could spread the absorption window. Taking melatonin on a relatively empty stomach at bedtime avoids this entirely.

The Wegovy prescribing information does not list melatonin among substances requiring dose adjustment or avoidance [2]. The Natural Medicines Comprehensive Database rates this combination as having no known interaction at standard melatonin doses [6].

Pharmacodynamic Overlap: Glucose Tolerance Is the Real Issue

The interaction that matters is pharmacodynamic, not pharmacokinetic. Both melatonin and semaglutide affect glucose and insulin signaling, but in different directions.

How Melatonin Affects Glucose

Melatonin receptors (MT1 and MT2) are expressed on pancreatic beta cells. Activation of MT2 receptors inhibits glucose-stimulated insulin secretion [7]. A 2020 study in Diabetologia (N=845) found that the MTNR1B rs10830963 risk allele, which increases MT2 receptor expression in beta cells, is associated with a 0.13 mmol/L higher fasting glucose and impaired early insulin response [7].

Exogenous melatonin at 5 mg reduced glucose tolerance by approximately 6% in a randomized crossover trial of 17 healthy women tested in the morning after a single nighttime dose [8]. A separate trial in The Journal of Pineal Research showed that 2 mg of prolonged-release melatonin taken nightly for 5 months did not significantly alter HbA1c or fasting glucose in adults with type 2 diabetes already on metformin [9].

What This Means in Practice

Dose matters. At 0.5 to 3 mg, melatonin's glucose-lowering effect on insulin secretion is small and clinically insignificant for most people. At 5 mg or above, the suppression of nocturnal insulin release becomes measurable. Semaglutide's glucose-lowering potency (HbA1c reduction of 1.6 percentage points at the 2.4 mg weight-management dose in STEP-2, N=1,210) is large enough to override a minor melatonin-driven glucose shift in most patients [10].

The practical decision framework: if a patient on Wegovy needs melatonin for sleep, start at 0.5 mg. Titrate to a maximum of 3 mg. Reserve doses above 3 mg only when lower doses fail, and recheck fasting glucose after 4 to 6 weeks at the higher dose.

Gastrointestinal Side Effects: Additive Nausea Risk

Nausea is Wegovy's most common adverse event. In the STEP-1 trial (N=1,961), 44.2% of participants on semaglutide 2.4 mg reported nausea, compared with 17.4% on placebo [11].

Melatonin's GI Profile

Melatonin can also cause nausea, headache, and daytime drowsiness, though at much lower rates. A 2022 Cochrane review of melatonin for preoperative anxiety (12 trials, N=1,264) reported nausea in 4% to 8% of melatonin-treated patients [12].

Managing Overlap

When both substances cause nausea, the effects may be additive. Patients in the dose-escalation phase of Wegovy (weeks 1 through 16) are most vulnerable. Spacing melatonin at least 30 to 60 minutes away from any food or other oral supplement reduces the chance of compounding GI discomfort.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "We tell patients starting GLP-1 agonists to introduce any new supplement one at a time and at the lowest dose, so we can isolate what's causing side effects if they appear" [13].

Dose-Separation and Timing Guidance

No formal dose-separation window is mandated by the FDA for melatonin and semaglutide. The two drugs operate on different timescales: Wegovy is injected once weekly and remains active continuously, while oral melatonin peaks in plasma within 20 to 60 minutes and is cleared within 4 to 6 hours [5].

Optimal Timing Strategy

Take Wegovy on your scheduled injection day at any consistent time. Take melatonin 30 to 60 minutes before your desired bedtime. No specific day-of-week avoidance relative to the Wegovy injection is necessary, since semaglutide's plasma levels are effectively steady-state after the first 4 to 5 weeks of weekly dosing [4].

If You Experience Nausea

On injection day, some patients find GI symptoms peak 12 to 72 hours after the dose. If melatonin-related nausea adds to this, shift the melatonin dose to start 48 hours after injection day and resume nightly once symptoms stabilize.

Who Should Be More Cautious

Most adults can combine these two agents without issue. Certain populations warrant closer monitoring.

Patients with Prediabetes or Type 2 Diabetes

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity in adults states that "glycemic monitoring should accompany any co-administered agent with glucose-modulating properties in patients with pre-existing dysglycemia" [14]. Melatonin qualifies under this guidance when used at doses above 3 mg.

Patients Taking CYP1A2 Inhibitors

Fluvoxamine, ciprofloxacin, and certain oral contraceptives inhibit CYP1A2 and can raise melatonin levels substantially. A study in Clinical Pharmacology & Therapeutics found that fluvoxamine increased melatonin AUC by approximately 17-fold [15]. Patients on these medications should use the lowest melatonin dose (0.3 to 0.5 mg) and inform their prescriber.

Older Adults

Adults over 65 metabolize melatonin more slowly. The American Academy of Sleep Medicine's 2017 clinical practice guideline conditionally recommends against melatonin for chronic insomnia in elderly patients, citing insufficient evidence of benefit and daytime sedation risk [16]. For older adults on Wegovy, behavioral sleep interventions (sleep hygiene, cognitive behavioral therapy for insomnia) should be tried before adding melatonin.

Monitoring Recommendations

Routine lab changes are not required for low-dose melatonin (0.5 to 3 mg) in otherwise healthy adults on Wegovy. Targeted monitoring is appropriate in specific scenarios.

When to Check Labs

Check fasting glucose and HbA1c if melatonin dose exceeds 3 mg nightly and the patient has prediabetes, type 2 diabetes, or a family history of diabetes. Recheck 4 to 6 weeks after starting or up-titrating melatonin.

What to Track Symptomatically

Monitor for excessive daytime sleepiness, vivid dreams, and morning grogginess. These suggest the melatonin dose is too high. Track GI symptoms during Wegovy dose escalation and note whether melatonin worsens nausea.

When to Discontinue Melatonin

Stop melatonin and consult a clinician if fasting glucose rises more than 15 mg/dL above baseline without another explanation, if daytime sedation impairs daily function, or if GI side effects become intolerable despite dose separation.

What the Research Still Needs to Clarify

No trial has randomized patients on semaglutide to melatonin versus placebo and measured glycemic or weight-loss outcomes. The available evidence is extrapolated from separate melatonin-glucose studies and the semaglutide STEP program.

A 2021 pilot study in Nutrients (N=37) explored melatonin supplementation during dietary weight loss and found no significant difference in weight lost at 12 weeks, though melatonin-treated subjects reported better sleep quality scores on the Pittsburgh Sleep Quality Index [17]. Whether improved sleep quality translates to better adherence to GLP-1 therapy remains unstudied.

The MTNR1B genotype question is also unresolved. Carriers of the rs10830963 G allele (approximately 30% of European-ancestry populations) have greater melatonin-induced glucose impairment [7]. Pharmacogenomic-guided melatonin dosing is not yet standard practice but may become relevant as GLP-1 use expands.

Bottom Line: Safe for Most, With Simple Precautions

Melatonin and Wegovy can be taken together. There is no pharmacokinetic interaction. The pharmacodynamic concern around glucose tolerance is dose-dependent and clinically minor at melatonin doses of 3 mg or below. Use the lowest effective melatonin dose, take it at bedtime on a light stomach, and recheck fasting glucose if you carry diabetes risk factors and use melatonin above 3 mg. Patients in the first 16 weeks of Wegovy dose escalation should introduce melatonin at 0.5 mg and increase only if needed.